Director of Research & Development
Dr Cindy Li
Immunologist and translational researcher driving cellular therapy innovation at Biosceptre — pioneering the BRiDGECAR™ universal CAR-T system to transform cancer treatment.
About
Dr Cindy Li studied medicine at Zhejiang University and worked as a trainee physician in a comprehensive oncology centre, before completing a PhD in Immunology and Haematology at the University of Sydney.
Her research has focused on the development of cellular therapies, with extensive experience in clinical grade CAR-T production and GMP compliant T cell therapy and cord blood unit production.
Dr Li also acts as a scientific consultant to an Australian human research ethics committee.
Research & Expertise
CAR-T Cell Therapy
Clinical grade CAR-T production targeting nfP2X7 — a cancer-specific biomarker expressed across most solid and liquid tumours.
BRiDGECAR™ Platform
Pioneering Biosceptre's universal CAR-T system combining nfP2X7-targeted CAR-T with multiple targeted antibodies.
GMP Manufacturing
GMP compliant cell therapy and cord blood unit production meeting regulatory standards for clinical trials.
Translational Research
Bridging laboratory discoveries to clinical applications — from pre-clinical validation to Phase I trials.
Ethics & Governance
Scientific consultant to an Australian human research ethics committee, ensuring research integrity.
R&D Leadership
Directing research strategy across multiple oncology programs targeting liquid and solid tumours.
Journey
Director of Research & Development
Biosceptre
Leading R&D strategy for Biosceptre's BRiDGECAR™ system — a multiple-targeted universal CAR-T platform with the potential to treat most forms of cancer. Overseeing programs targeting liquid and solid tumours, working alongside a world-class advisory board including a Nobel Laureate.
Doctor of Philosophy — Immunology & Haematology
University of Sydney
Research focused on cellular therapies, with extensive experience in clinical grade CAR-T production and GMP compliant T cell therapy and cord blood unit production.
Medicine (MBBS)
Zhejiang University
Medical degree with clinical training as a trainee physician in a comprehensive oncology centre, providing foundational understanding of cancer biology and patient care.
Publications
Selected peer-reviewed publications and research contributions
The Current Landscape of Modular CAR T Cells
Biosceptre (Aust) Pty Ltd., Westmead, NSW, Australia
Int J Mol Sci. 2025;26(24):11898
Development of CAR T Cell Therapy in Children — A Comprehensive Overview
Ziduo Li et al.
J Clin Med. 2022;11(8):2158
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
Ziduo Li et al.
Blood. 2021;138(16):1391-1405
Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant
Ziduo Li et al.
Clin Transl Immunology. 2021;10(3):e1249
Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity
Ziduo Li et al.
Blood Adv. 2020;4(14):3443-3456
Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody
Ziduo Li et al.
Clin Transl Immunology. 2020;9(7):e1156
CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential
Ziduo Li, X Ju, PA Silveira, E Abadir, M-H Hsu, D Hart, GJ Clark
Front Immunol. 2019;10:1312
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Ziduo Li, X Ju, K Lee, C Clarke, JL Hsu, E Abadir, CE Bryant, S Pears, N Sunderland, S Heffernan et al.
Haematologica. 2018;103(4):655-665
The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population
Ziduo Li et al.
J Immunol. 2016;197(12):4613-4625
A circulating tumor cell cluster-based model for tumor metastasis (Hypothesis)
Ziduo Li et al.
Oncol Lett. 2016;12(6):4891-4895
Get in Touch
Interested in collaboration, consulting, or connecting on research? I'd love to hear from you.